2244864-88-6

2244864-88-6 structure

Name: Sitravatinib malate
Chemical Name: Sitravatinib malate
CAS Number: 2244864-88-6
Molecular Formula: C₃₇H₃₅F₂N₅O₉S
Molecular Weight: 763.76
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK c-Kit
Create Date: 2020-01-23 12:35:51
Modify Date: 2025-08-22 14:12:30
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively[1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment[2].

Name	Sitravatinib malate

Description	Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively[1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3 Research Areas >> Inflammation/Immunology Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Trk Receptor Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Discoidin Domain Receptor
Target	Axl:1.5 nM (IC50) MER:2 nM (IC50) VEGFR3:2 nM (IC50) VEGFR2:5 nM (IC50) VEGFR1:6 nM (IC50) TrkA:5 nM (IC50) TrkB:9 nM (IC50) KIT:6 nM (IC50) FLT3:8 nM (IC50) DDR2:0.5 nM (IC50) DDR1:29 nM (IC50)
In Vitro	Sitravatinib (0.01 nM-10 μM; 14 days) reduces colony formation in a dose-dependent manner in KLN205 and E0771 cell lines[2]. Sitravatinib (0.001-10 μM; 5 days) inhibits tumor cell viability with IC50s of approximately 1 μM in KLN205, E0771 and CT1B-A5 cell lines[2]. Cell Viability Assay[2] Cell Line: KLN205, E0771, CT1B-A5 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 5 days Result: Inhibited KLN205, E0771, CT1B-A5 cells with IC50s of approximately 1 μM.
In Vivo	Sitravatinib (20 mg/kg; p.o.; once per day for 6 days) significantly inhibits tumor progression and induces tumor regression in C57BL/6 mice bearing CT1B-A5 cells model[2]. Animal Model: 6-week-old C57BL/6 mice (bearing CT1B-A5 cells)[2] Dosage: 20 mg/kg Administration: Oral administration; once per day for 6 days Result: Significantly inhibited tumor progression and induced tumor regression.
References	[1]. Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109. [2]. Du W, et al. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018 Nov 2;3(21). pii: 124184.

Molecular Formula	C₃₇H₃₅F₂N₅O₉S
Molecular Weight	763.76

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2244864-88-6	1123837-84-2
617-55-0	23247-36-1
877303-64-5	1256377-67-9
78644-42-5	9067-93-0
816-68-2	32099-14-2
2680800-82-0	2680801-03-8
2680801-14-1	2680674-26-2
2680760-18-1	2679826-09-4
1213397-98-8	2171783-81-4
1691173-55-3	1822790-41-9